Member Info for WeTookPelham

one other thought, there appears to be no call for patients to keep silent about the trial/nda's in place then.

although the conspi****** in me wonders why it's the first post on mcmillan for a while and it coincides with the conferences. but yes, obviously more likely it's because the patient had something to talk about.

As alluded to by marcusl2/others here this patient RE reaction, what cohort is she in exactly? High dose combo with checkpoint inhibitor?

Thanks miavoce. Have I made the correct assumption however?

A recent update, patient mentioning the state of her arm following the four injections. This is the something something(dtc?) abbreviation that shows a good response I believe?

https://community.macmillan.org.uk/cancer_experiences/living-with-incurable-cancer-forum/f/diagnosis-and-treatment/255499/the-modify-study?pifragment-15926=2#pifragment-15926=1

Think you might be on to something there crumbs, it would a perfect time for an update, so I wouldn't be too surprised if it coincided.

However...I would rather trial updates and news of an $8b takeover tomorrow AM...but I guess I can just about stretch it 'til Tuesday ;)

Been here long enough to say I personally would be happy for the whole lot to be bought out for say $2/3b, even though, relative to other similar small bio deals, that would be very cheap.

Agree Krafty, but isn't bio23 more(soley) for discussions about partnering and deals?

Perhaps AACR/ASCO lay the groundwork regarding outlining Moditope results? And then Bio23 is when big pharma can say yes we like what we saw at AACR/ASCO?

Just hypothesising/guessing mind you.

Interesting how the conference's are all closely timed together though.

Yep hopefully.

But either way it seems like meetings took place between Scancell and other parties, one way or another.

"and our valuation compared to US companies must surely entice someone to take a punt !"

You would think!

Actually reading your past tense, I didn't appreciate the conference is coming to a close today already!

But yes indeed, how many of those did Scancell take advantage of, or even taking advantage of today perhaps.

Https://www.bio.org/events/bio-international-convention/one-one-partneringtm

Https://www.bio.org/events/bio-international-convention

Scroll down this page.

So there appears to be 2 x lists of attendees, a global list of everyone attending:

"What Companies are Attending BIO 2023?

Interested to see what companies are attending BIO 2023 in Boston? Search the latest list of companies that is updated on a weekly basis. "

And another searchable list of Companies in the Partnering System, which is a far smaller list of companies:

"Companies in the Partnering System

Search the latest list of companies that have profiles in the BIO One-on-One PartneringTM System and request a meeting."

Scancell are in the latter also. Might be stating the obvious, but it appears they are not merely attending?

"Dr Miller is high calibre...for him to stand Infront of a poster that had far less info on it than the AACR one doesn't make sense until you factor in BIO2023...and that he is obviously happy to be associated with the ModiFY trial".

Yes it did seem unsual that Dr Miller was presenting the poster at ASCO. No disrepect to Fayaz Master

(Head of Clinical Operations) who did AACR, but Dr Miller is as you say seems very high calibre to be presenting a poster?

"A thought The recent poster was supposed to be and oral abstract delivered by the trial Investigator C Ottenmesier ( hope correct spelling ) changed to "The poster, being presented by Dr Robert Miller, Medical Director,

Someone referred previously a NDA , So did he have to be tight lipped on further results .? this a question for the posters to consider or is IT just wishful thinking on my part ?"

Similarly, why did this switch happen? Hopefully we find out soon.

....appears one of the recent trialists has started blogging about it. Search for "ModiFY Trial Day 1"

Well we can safely say nobody attends a huge partnering conference without good reason anyway.

Can someone remind me, didn't the Genmab deal come very shortly after or during a conference? If so which one was it?

"05/6/2023

15:34 marcusl2: Kam Zaki

@drkamzaki

·

16h

consented first patient this week to the RCC modi-1 and CPI cohort

@UHSx_Research

HTTPS://twitter.com/drkamzaki/status/1665473939869499392?s=20"

Interesting that the trial is now all of a sudden getting more social media traction? Why didn't Dr's previously flag they were submitting their patients to the trial?

Is it something to do with the fact Dr. Christian O and his colleagues are (?) external trial managers?

Nice find crumbs!

Although isn't it odd it doesn't mention "Scancell" by name? Only "modify"?

We all know Scancell like to stay under the radar but that's taking the biscuit!

RR my point was, as Markingtime alluded to was more the change in PR/strategic partnership company and it's connotations. RE timing of news, well we are all making best guesses there.